Tumor cells engineered to express major histocompatibility complex class II molecules induce T helper cell-dependent responses that protect mice from normally lethal doses of unmodified tumor cells
- PMID: 8769713
Tumor cells engineered to express major histocompatibility complex class II molecules induce T helper cell-dependent responses that protect mice from normally lethal doses of unmodified tumor cells
Abstract
Tumor cells typically fail to stimulate protective immune response in the autochthonous host. This does not appear to be the result of either inadequate antigenicity or failure to express a normal complement of major histocompatibility complex (MHC) class 1 molecules. To investigate if tumor cells fail to stimulate protective immunity because they fail to activate adequate numbers of T helper cells, we transfected murine fibrosarcoma and melanoma cells with genes encoding syngeneic and allogeneic MHC class II molecules. Fibrosarcoma cells expressing either type of MHC class II molecules failed to induce tumors in syngeneic mice and stimulated T helper cell-dependent antitumor immune responses that protected mice from subsequent challenge with untransfected tumor cells. The antitumor response involved both CD4+ and CD8+ T cells, and appeared to be dependent on at least low levels of innate tumor cell immunogenicity.
Similar articles
-
Fibrosarcoma cells expressing allogeneic MHC Class II antigens induce protective antitumor immunity.J Immunol. 1995 Jan 15;154(2):738-43. J Immunol. 1995. PMID: 7814880
-
Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2.J Immunol. 1993 Jul 1;151(1):244-55. J Immunol. 1993. PMID: 8326126
-
Turning tumor cells in situ into T-helper cell-stimulating, MHC class II tumor epitope-presenters: immuno-curing and immuno-consolidation.Cancer Treat Rev. 2004 May;30(3):281-90. doi: 10.1016/j.ctrv.2003.08.002. Cancer Treat Rev. 2004. PMID: 15059651 Review.
-
Active CD4+ helper T cells directly stimulate CD8+ cytotoxic T lymphocyte responses in wild-type and MHC II gene knockout C57BL/6 mice and transgenic RIP-mOVA mice expressing islet beta-cell ovalbumin antigen leading to diabetes.Autoimmunity. 2008 Nov;41(7):501-11. doi: 10.1080/08916930802069256. Autoimmunity. 2008. PMID: 18855194
-
MHC class II-restricted tumor antigens recognized by CD4+ T cells: new strategies for cancer vaccine design.J Immunother. 2001 May-Jun;24(3):195-204. J Immunother. 2001. PMID: 11394496 Review.
Cited by
-
Specific immunotherapy of cancer in elderly patients.Drugs Aging. 2001;18(9):639-64. doi: 10.2165/00002512-200118090-00002. Drugs Aging. 2001. PMID: 11599633 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials